What is the optimal duration of therapy in stage III colon cancer patients?
Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Should stage lll colon cancer patients be treated with 3 months or 6 months of FOLFOX therapy?
Howard Hochster, MD of Yale Cancer Center discusses whether or not stage III colon cancer patients should be treated with either 3 months or 6 months of FOLFOX therapy. This was recorded at the 2017 A...
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Approaches to treating BRAF-mutated positive CRC patients
Howard Hochster, MD of Yale Cancer Center gives an overview of treatments for BRAF-mutated positive colorectal cancer patients at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Determining the optimal duration of therapy in a stage III colon cancer patient
Richard M. Goldberg, MD, FASCO of West Virginia University Cancer Institute discusses the optimal duration of therapy for a stage III colon cancer patient. This was recorded at the 2017 ASCO Annual Me...
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
High-risk versus low-risk stage III colon cancer patients
Richard M. Goldberg, MD, FASCO of West Virginia University Cancer Institute explains how he defines a high-risk from a low-risk stage III colon cancer patient at the 2017 ASCO Annual Meeting in Chicag...
Author: obr
Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts
Good IDEA: Drop Adjuvant Chemo From 6 to 3 Months in CRC
Dr John Marshall reports on the practice-changing results of the IDEA study in stage III colorectal cancer looking at duration of adjuvant chemotherapy, as presented at the ASCO plenary session. (Source: Medscape Oncology)
Source: Medscape Oncology - June 12, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Difference Between Right and Left Sided Primary Colon Cancers in Patients with Metastatic Disease
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of his presentation, which focused on the difference between left and right sided tumors in patients with c...
Author: ASCO2017
Added: 06/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO 2017 to Present Adjuvant Therapy for Stage III Colon Patients
Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of the exciting presentations discussed at ASCO this year. One particular presentation he is most intereste...
Author: ASCO2017
Added: 06/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 4, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Regorafenib (Stivarga) in Advanced Colorectal Cancer
Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of three abstracts that discussed the use of regorafenib (stivarga) in advanced colorectal cancer. This was recorded at...
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Importance of Early Molecular Testing in Colon Cancer
Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testin...
Author: GiDebates2017
Added: 06/01/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Is Circulating Tumor DNA Ready to Guide Adjuvant Therapy in Colon Cancer?
Cathy Eng, MD, FACP of MD Anderson Cancer Center gives an overview of her first presentation, Is Circulating Tumor DNA Ready to Guide Adjuvant Therapy in Colon Cancer, which was debated with Dr. Axel ...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Role of Aspirin Therapy in GI Cancer Survivors & amp; the General Population
Zsofia K. Stadler, MD of Memorial Sloan-Kettering explains the role of aspirin therapy in patients with colon cancer and other GI malignancies. This was recorded at the 2017 Great Debates and Updates ...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Availability of Novel Targets for Metastatic Colorectal Cancer
Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his first presentation, which focused on the availability of new novel agents and therapies for managing patients with metastatic co...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
Treatment of Left-Sided Tumors versus Right-Sided Tumors in Colorectal Cancer
Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his presentation which focused on how to treat left-sided tumors versus right-sided tumors in colorectal cancer. This was recorded...
Author: GiDebates2017
Added: 05/26/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 26, 2017 Category: Cancer & Oncology Source Type: podcasts
